Zheng et al. reported that intracranial progression-free survival (iPFS) in patients with LM from NSCLC was higher in those harboring the EGFR exon 19 deletion (11.9 months) than in those with EGFR exon 21 L858 mutation (2.8 months). This evidence concerns the gene EGFR and non-small cell lung carcinoma.